All Title Author
Keywords Abstract

First Nationwide Survey on the Resistance to First Line Anti-Tuberculosis Drugs in Ghana

DOI: 10.4236/jtr.2018.61007, PP. 68-80

Keywords: Tuberculosis, National Survey, Drug Resistance, Ghana

Full-Text   Cite this paper   Add to My Lib


Background/objective: A nationwide survey on the resistance to first line anti-tuberculosis (anti-TB) drugs was conducted in Ghana from 2007-2008 by Noguchi Memorial Institute for Medical Research in collaboration with the National Tuberculosis Control Programme. We aimed to characterize mycobacterial species causing pulmonary tuberculosis (PTB) and determine the resistance pattern to first line anti-TB drugs among newly diagnosed and previously treated PTB patients in Ghana. Methods: Two sputum samples from consented new smear positive PTB patients who had never been treated for TB or had been on anti-TB treatment for less than a month and patients who had been treated for TB previously for more than a month in selected diagnostic centres nationwide were collected for culture, identification and drug susceptibility test. Culture positive isolates were tested against streptomycin (S), isoniazid (H), rifampicin (R) and ethambutol (E) using the simplified proportion method and line probe assay (LPA). The LPA was performed in mid-2017. Results: Among 410 samples, 345 positive cultures were obtained and identified as Mycobacterium tuberculosis complex (MTBC). Of the 345 isolates, 133 were further differentiated by GenoType MTBC® as M. tuberculosis, 126 (94.7%) and M. africanum 7 (5.3%). The overall drug resistance patterns were as follows: 43/345 (12.5%), 6/345 (1.7%), 9/345 (2.6%) and 71/345 (20.6%) were resistant to H, R, E and S respectively and 5/345 (1.4%) were multi-drug resistant (MDR). Conclusion: The results indicate high levels of resistance to S and H among new and previously treated TB patients. We recommend adequate surveillance systems including periodic national anti-TB drug resistance surveys.


[1]  National Tuberculosis Programme (2001) Tuberculosis Control Strategic Plan for Ghana. Ministry of Health, Accra.
[2]  World Bank Data. Incidence of Tuberculosis (per 100,000 People).
[3]  National Tuberculosis Programme (2011) Plan to Initiate and Expand Drug Resistant TB Management in Ghana. Ghana Health Service, Accra.
[4]  National Tuberculosis Programme (2003) Annual Tuberculosis Report. Ghana Health Service/Ministry of Health, Ghana.
[5]  van der Werf, T.S., Groothuis, D.G. and van Kingeren, B. (1989) High Initial Drug Resistance in Pulmonary Tuberculosis in Ghana. Tubercle, 70, 249-255.
[6]  Lawn, S.D., Frimpong, E.H., Al-Ghusein, H., et al. (2001) Pulmonary Tuberculosis in Kumasi, Ghana: Presentation, Drug Resistance, Molecular Epidemiology and Outcome of Treatment. West African Journal of Medicine, 20, 92-97.
[7]  World Health Organization (2003) Guidelines for Surveillance of Drug Resistance in Tuberculosis, WHO/CDS/2003.3. World Health Organization, Geneva.
[8]  World Health Organization (2003) Treatment of Tuberculosis Guideline for National Programmes. 3rd Edition, WHO/CDC/TB/2003. 313, World Health Organization, Geneva.
[9]  Instructions for Use for GenoType Mycobacterium MTBC.
[10]  Instructions for Use for GenoType Mycobacterium MTBDRplus.
[11]  Dosso, M., Bonard, D., Msellati, P., et al. (1999) Primary Resistance to Antituberculosis Drugs: A National Survey Conducted in Cote d’Ivoire in 1995-1996. International Journal of Tuberculosis and Lung Disease, 3, 805-809.
[12]  Bretzel, G., Aziz, M., Wendl-Richter, U., et al. (1999) Anti Tuberculosis Drug Resistance Surveillance in Uganda 1996-1997. International Journal of Tuberculosis and Lung Disease, 3, 810-815.
[13]  Yeboah-Manu, D., Asante-Poku, A., Bodmer, T., et al. (2011) Genotypic Diversity and Drug Susceptibility Patterns among M. tuberculosis Complex Isolates from South-Western Ghana. PLOS ONE, 6, e21906.
[14]  Niemann, S., Richter, E. and Rüsch-Gerdes, S. (2000) Differentiation among Members of the Mycobacterium tuberculosis Complex by Molecular and Biochemical Features: Evidence for Two Pyrazinamide-Susceptible Subtypes of M. bovis. Journal of Clinical Microbiology, 38, 152-157.
[15]  Kehinde, A.O., Obaseki, F.A., Ishola, O.C., et al. (2007) Multidrug Resistance to Mycobacterium tuberculosis in a Tertiary Hospital. Journal of National Medical Association, 99, 1185-1189.
[16]  Owusu-Dabo, E., Adjei, O., Meyer, C., et al. (2006) Mycobacterium tuberculosis Drug Resistance, Ghana. Emerging Infectious Diseases, 12, 1170-1172.
[17]  World Health Organisation (2007) Anti Tuberculosis Drug Resistance in the World. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. WHO/TB/97.229, World Health Organization, Geneva.
[18]  Mwinga, A. (2001) Drug-Resistant Tuberculosis in Africa. Annals of New York Academy of Science, 953, 106-112.
[19]  Diande S., Sangare L., Kouanda S., et al. (2009) Risk Factors for Multidrug-Resistant Tuberculosis in Four Centers in Burkina Faso, West Africa. Microbiology Drug Resistance, 15, 217-221.


comments powered by Disqus

Contact Us


微信:OALib Journal